Regeneron Pharmaceuticals Overview
Latest ROE for Regeneron Pharmaceuticals: 13650468.29% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow13650468.29%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, REGN shows a ROE of 13650468.29%. That is above the Healthcare sector average of -100.59%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about -100.59%. Regeneron Pharmaceuticals is at 13650468.29%, which is higher that average. That is roughly 13570723.6% above the sector mean. Use the comparison chart on this page to see how REGN stacks up against individual peers as well.
Check the historical chart to see whether REGN's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Regeneron Pharmaceuticals with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Regeneron Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 13650468.29%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about -100.59%, while REGN is at 13650468.29%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
